Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MYC drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MYC Recombinant Protein (bHLHZip Domain, Full-length) — wild-type and mutant (T58A, R367A, etc.) available. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View MYC Products |
| Gene Delivery | MYC Promise-ORF / Lentivirus Premade Particles. Full-length ORF for stable cell line construction. | View MYC Products |
| Benchmark Ab | Anti-MYC Benchmark Antibody (recombinant 9E10 clone and Omomyc peptide mimetic sequence) — positive controls for Western blot, IP, and PPI disruption assays. | View MYC Products |
| Validator | MYC siRNA Set — for knockdown verification and specificity controls. | View MYC Products |
| MAX | Obligate heterodimer partner for MYC DNA binding and transcriptional activity. Required for dimerization assays. | View MAX Products |
| BRD4 | Epigenetic reader often targeted to indirectly suppress MYC transcription. Synthetic lethality partner. | View BRD4 Products |
| CDK9 | Transcriptional CDK (P-TEFb component). Indirect MYC suppression target. | View CDK9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| MYC-MAX PPI Disruption | High-purity soluble MYC and MAX proteins (bHLHZip domain). CD spectroscopy validated folding. Human/mouse/cynomolgus orthologs available. >95% purity. |
| Subfamily Selectivity (vs MYCN/MYCL) | Homolog panel (c-MYC, N-MYC, L-MYC) strictly verified by mass spectrometry for cross-reactivity screening. |
| Transcriptional vs Degradation Mechanism | DNA-binding deficient mutant (R367A) available for mechanistic dissection. |
| Oncogenic Mutant Profiling (T58A, etc.) | MYC T58A and other key mutants (e.g., rs4645959, rs121918684, rs28933407) available for drug sensitivity and resistance studies. |
| PROTAC / Degrader Screening | Endogenous-like HEK293 expressed full-length MYC protein (native post-translational modifications). Ideal for ternary complex formation assays. |
| Lack of Controls | Benchmark recombinant antibodies and clinical-grade peptide mimetics (Omomyc-derived) included for reliable assay normalization. |
| False Positives in Reporter Assays | Sequence-verified plasmids and validated siRNA included for rigorous specificity checks. |
Global Clinical Landscape & Future Outlook
The race for MYC therapeutics is intensifying, with major players shifting focus from indirect transcriptional suppression (e.g., BRD4, CDK9 inhibitors) toward direct protein-protein interaction (PPI) inhibitors, dominant-negative peptides (e.g., Omomyc), and targeted protein degradation (TPD) platforms. Long considered "undruggable" due to its intrinsically disordered structure, MYC is now being addressed via molecular glues, PROTACs, and miniproteins. As first-generation direct inhibitors reach the clinic, the next wave of R&D targets dual degradation pathways, combination regimens with BCL-2, BET, and cell-cycle inhibitors, and synthetic lethality approaches. Critical resistance mutations (e.g., T58I, R367A) identified in patient samples underscore the need for mutant-specific assay tools.
Key Mutations and Clinical Implications
MYC (c-MYC) harbors several clinically relevant mutations in the bHLHZip domain, often found in Burkitt lymphoma and other MYC-driven malignancies (evidence: UniProt P01106):
- rs4645959 (Thr58Ile): A well-characterized stabilizing mutation that increases MYC protein half-life and transcriptional activity (UniProt VAR_016327).
- rs121918684: A Burkitt lymphoma-associated mutation (UniProt VAR_063384).
- rs28933407: Another Burkitt lymphoma sample mutation (UniProt VAR_063385).
These mutations highlight the importance of using mutant-specific protein reagents for preclinical drug screening and resistance mechanism studies. TarMart provides both wild-type and mutant bHLHZip domain proteins for these assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Direct PPI Inhibitors (Small Molecule, Peptide) | Peptomyc, PeptiDream, Aurigene | Solid Tumors, Lymphoma | MYC-MAX Dimerization Assay (need purified bHLHZip domains) |
| Molecular Glues / PROTACs | Arvinas, C4 Therapeutics | Refractory Cancers, Breast Cancer | Ternary Complex Formation (need high-purity full-length and domain constructs) |
| Indirect Transcriptional Inhibitors (BET, CDK9) | Syros, Zenith, Constellation | Hematologic Malignancies, MYC-amplified Tumors | DNA Binding Competition & Reporter Assays (need mutant vs WT proteins, lentivirus models) |
| Synthetic Lethality Combinations | Various academic & pharma | MYC-High Tumors | Pathway Panel Assays (need CDK9, BRD4, MAX proteins for combination screens) |
Live MYC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: